EGFR and cancer: Our meta-analysis demonstrating the benefit of EGFR-TKI in the rechallenge scenario may be of special value in locations with limited access to new therapeutic developments, but research and initiatives to increase access to cancer therapies and oncological care around the world should grow concurrently with new drug development efforts.